President and CEO of Arrowhead Research Corporation to Attend Roth Capital Partners Conference

Arrowhead (NASDAQ: ARWR) ("Arrowhead") President and Chief Executive Officer Dr. Christopher Anzalone will be in attendance at the 21st Annual Roth Capital Partners OC Growth Stock Conference in Dana Point, California on Tuesday, February 17, 2009 and will be available to meet with members of the investment community. Arrowhead is a nanotechnology company that is commercializing new technologies in the areas of life sciences, electronics, and energy. As owners of key nanotechnology assets in these markets, Arrowhead and its subsidiaries are well-positioned to capitalize on a significant market opportunity. Key partners and customers include Samsung Electronics, Tokyo Electron, Entegris, Inc. and The Battelle Memorial Institute.

To arrange a meeting with Dr. Anzalone at the Growth Stock Conference, please contact: Virginia Dadey; Vice President, Investor Relations Telephone: 212.541.3707 Email: [email protected]

Arrowhead is building value for shareholders through the progress of majority owned subsidiaries founded on nanotechnologies originally developed at universities. The Company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Arrowhead currently has two wholly owned subsidiaries (the "Subsidiaries"), two majority-owned subsidiaries and has minority investments in two development stage nanotechnology companies. The Company's Subsidiaries seek to commercialize a variety of nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, carbon-based electronics and fullerene antioxidants. The Company's minority investments are focused on developing advanced nanomaterials for spinal cord injury and wound healing and drug delivery technology.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback